Immunoglobulin E specific for Atriplex polycarpa pollen (IgE (Atriplex polycarpa))

Immunoglobulin E (IgE) specific for Atriplex polycarpa pollen epitopes is a key mediator of allergic sensitization to the Desert Saltbush, a common shrub in arid regions like the Southwestern United States. These antibodies are produced by B cells upon exposure to pollen allergens and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to Atriplex polycarpa pollen, the allergen cross-links the surface-bound IgE, triggering the release of inflammatory mediators such as histamine and leukotrienes. This process results in clinical symptoms of pollinosis, including allergic rhinitis and asthma. Therapeutic strategies targeting this molecule include the use of anti-IgE monoclonal antibodies, which sequester free IgE to prevent cellular activation, and allergen-specific immunotherapy, which seeks to desensitize the immune system to the specific epitopes of the pollen. Monitoring levels of these specific IgE antibodies is a standard diagnostic tool for identifying saltbush-related allergies.

Other names

Allscale pollen-specific IgEDesert saltbush pollen-specific IgEAtriplex polycarpa IgEAnti-Atriplex polycarpa IgE

Monoclonal antibodies like Omalizumab bind to the Fc region of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy (AIT) using Atriplex polycarpa extracts aims to induce immune tolerance by shifting the response from a Th2-mediated IgE production toward a Th1/Treg-mediated response, increasing protective IgG4 antibodies.